Christian Ottmann is scientific co-funder and chief technology officer at Ambagon Therapeutics and associate professor for molecular cell and structural biology at Eindhoven University of Technology, The Netherlands. He works on small molecules that stabilize protein-protein interactions involving an adapter protein called 14-3-3. He was involved in several early drug-discovery projects with the pharmaceutical industry and coordinated the FP7 Industry-Academia Partnership and Pathways (IAPP) 14-3-3STABS project and the Horizon2020 European Training Network (ETN). Targeted Small Molecule Stabilization of Protein-Protein Interactions (TASPPI) project. Before joining Eindhoven, he was a group leader at the Chemicals Genomics Centre (CGC) of the Max Planck Society in Dortmund, Germany. He obtained his PhD (summa cum laude) in 2003 from the University of Tübingen. He received the Innovation Award in Medicinal/Pharmaceutical Chemistry of the GDCh/DPhG in 2012 and the Young Chemical Biology Award of the International Chemistry Biology Society (ICBS) in 2013.
Exploring the Use of Molecules that Stabilize the Interaction between LRRK2 Kinase and the 14-3-3 Adapter Protein as a Neuroprotective Therapy for Parkinson’s Disease